D. Garwacki

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

D. Arnold, S. Muley, P. Vermersch, 2018, The Lancet Neurology.

Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab

J. Pula, J. Kattah, D. Garwacki, 2014, Journal of the Neurological Sciences.

Treating acute stroke patients with intravenous tPA. The OSF stroke network experience.

J. Milbrandt, David Z. Wang, D. Garwacki, 2000, Stroke.

Demyelinating disease of corpus callosum presenting as glioma on magnetic resonance scan: a case documented with pathological findings.

D. Garwacki, U. Kalyan-Raman, P. Elwood, 1987, Neurosurgery.